☰

immunodeficiency and immunopathological disorders

‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA
Adverse effects of COVID-19 vaccines and measures to prevent them
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines
Alternate mechanisms of mRNA vaccine toxicity: which one is the main culprit?
Anti-recoverin Antibody-Associated Post-acute COVID Vaccination Syndrome After BNT162b2 in HLA-B27-Positive Spondylarthritis: A Case Report
Antiviral treatments [Molnupiravir] lead to the rapid accrual of hundreds of SARS-CoV-2 mutations in immunocompromised patients
Autoimmune and Neoplastic Outcomes After the mRNA Vaccination: The Role of T Regulatory Cell Responses
BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists
Bombshell: Pfizer’s Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021
BREAKING PUBLICATION: mRNA “Vaccines” May Prime the Body for YEARS of Amplified Harm from Subsequent SARS-CoV-2 Infections
Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2 - A Multidisciplinary Perspective
Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination
Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history
Comirnaty Facts: Mechanisms of action and damage potential
Compilation: Peer Reviewed Medical Papers of COVID Vaccine Injuries
Concern about the Effectiveness of mRNA Vaccination Technology and Its Long-Term Safety: Potential Interference on miRNA Machinery
COVID Injections: Unveiling the Mechanisms of Harm
COVID-19 Injections: Harms and Damages, a Non-Exhaustive Conclusion
COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 1
COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 2
COVID-19 mRNA “vaccine” harms research collection
COVID-19 vaccines – An Australian Review
Dr David Bauer: ‘Pfizer vaccine produces fewer key antibodies’ – MSN News
Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination
Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients
Excitotoxicity (Immunoexcitotoxicity) as a Critical Component of the Cytokine Storm Reaction in Pulmonary Viral Infections, Including SARS-Cov-2
Exploring the possible link between the spike protein immunoglobulin G4 antibodies and cancer progression
Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice
Hemophagocytic Lymphohistiocytosis (HLH) Flare Following the COVID-19 Vaccine: A Case Report
Homology between SARS CoV-2 and human proteins
Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program
Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination
Immune-mediated adverse events post-COVID vaccination and types of vaccines: a systematic review and meta-analysis
Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination
Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The role of G-quadruplexes, exosomes and microRNAs
Messenger RNA SARS-CoV-2 Vaccines Affect the Gut Microbiome
Metastatic prostatic adenocarcinoma presenting as generalized lymphadenopathy unmasked by a COVID booster vaccine
mRNA Moratorium NOW!
mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review
mRNA Vaccine Toxicity
National Academies Committee on Review of Relevant Literature Regarding Adverse Events Associated with Vaccines March 30 2023: Written material accompanying oral remarks
Need for validation of vaccination programs
New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review
Oncogenesis and autoimmunity as a result of mRNA COVID-19 vaccination
Pathogenic antibodies induced by spike proteins of COVID-19 and SARS-CoV viruses
Persistence of S1 Spike Protein in CD16+ Monocytes up to 245 Days in SARS-CoV-2 Negative Post COVID-19 Vaccination Individuals with Post-Acute Sequalae of COVID-19 (PASC)-Like Symptoms
Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion
Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults
Repeated COVID-19 Vaccination as a Poor Prognostic Factor in Pancreatic Cancer: A Retrospective, Single-Center Cohort Study
1014